Mixed connective tissue disease - a subset with sequential clinical and laboratory features

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Mixed connective tissue disease (MCTD) is an autoimmune disorder with overlapping features of systemic lupus erythematosus (SLE), polymyositis, and rheumatoid arthritis.
• The clinical and serological presentation of MCTD can be variable and may change over time.
• Extractable nuclear antigen (ENA) antibodies, particularly anti-ribonucleoprotein (RNP), are key diagnostic markers for MCTD.

Purpose of the Study:

• To investigate the longitudinal clinical and serological changes in patients initially diagnosed with or suspected of having MCTD.
• To document the sequential development of specific disease features and antibody profiles over time.
• To emphasize the importance of serial assessment in managing patients with potentially evolving autoimmune conditions.

Main Methods:

• Retrospective analysis of 23 patients with initial MCTD features.
• Monitoring of clinical manifestations and serological markers, including ENA and antinuclear antibody (ANA) titers.
• Detailed examination of antibody variations, such as anti-RNP and anti-Sm, and ANA patterns over time.

Main Results:

• All patients had high-titer anti-RNP antibodies; 9 showed titer variations, and 3 had transient anti-Sm antibodies.
• Four patients initially presented with other diagnoses and negative ANA tests before developing speckled ANAs.
• Eleven patients consistently exhibited speckled ANA patterns, while clinical features evolved, mimicking SLE, polymyositis, or rheumatoid arthritis.

Conclusions:

• MCTD is a dynamic condition that can manifest significant clinical and serological evolution.
• Serial monitoring of clinical and serological parameters is crucial for accurate diagnosis and management of MCTD.
• The study underscores the variability in ENA antibody titers and ANA patterns over the disease course.